184 related articles for article (PubMed ID: 38427665)
1. Exploration of adverse events associated with risdiplam use: Retrospective cases from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Yu L; Liu L
PLoS One; 2024; 19(3):e0298609. PubMed ID: 38427665
[TBL] [Abstract][Full Text] [Related]
2. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
Yin Y; Shu Y; Zhu J; Li F; Li J
Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
[TBL] [Abstract][Full Text] [Related]
3. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.
Shu Y; Chen J; Ding Y; Zhang Q
Front Immunol; 2023; 14():1169735. PubMed ID: 37256136
[TBL] [Abstract][Full Text] [Related]
4. Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study.
Zhuang W; Lu M; Wu Y; Chen Z; Wang M; Wang X; Guan S; Lin W
Clin Drug Investig; 2023 Dec; 43(12):949-962. PubMed ID: 37995087
[TBL] [Abstract][Full Text] [Related]
5. Data mining and safety analysis of avatrombopag: a retrospective pharmacovigilance study based on the US food and drug administration's adverse event reporting system.
Zhu H; Wu M
Sci Rep; 2024 May; 14(1):11262. PubMed ID: 38760419
[TBL] [Abstract][Full Text] [Related]
6. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
7. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
Nagai J; Ishikawa Y
PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
[TBL] [Abstract][Full Text] [Related]
8. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
Zhang S; Wang Y; Qi Z; Tong S; Zhu D
Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
[TBL] [Abstract][Full Text] [Related]
9. Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System.
Matsumoto J; Iwata N; Watari S; Ushio S; Shiromizu S; Takeda T; Hamano H; Kajizono M; Araki M; Nasu Y; Ariyoshi N; Zamami Y
Eur Urol Focus; 2023 Jan; 9(1):141-144. PubMed ID: 35915038
[TBL] [Abstract][Full Text] [Related]
10. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
Shu Y; Ding Y; Dai B; Zhang Q
Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
[TBL] [Abstract][Full Text] [Related]
11. Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database.
Yin G; Song G; Xue S; Liu F
Sci Rep; 2024 May; 14(1):11367. PubMed ID: 38762547
[TBL] [Abstract][Full Text] [Related]
12. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
13. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany.
Hahn A; Günther R; Ludolph A; Schwartz O; Trollmann R; Weydt P; Weiler M; Neuland K; Schwaderer MS; Hagenacker T;
Orphanet J Rare Dis; 2022 Jul; 17(1):276. PubMed ID: 35854272
[TBL] [Abstract][Full Text] [Related]
14. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
[TBL] [Abstract][Full Text] [Related]
15. Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang M; Cheng Q; Shi X; Sun MH
Expert Opin Drug Saf; 2024 Mar; 23(3):353-362. PubMed ID: 37610085
[TBL] [Abstract][Full Text] [Related]
16. Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system.
Zhao Y; Jiang H; Xue L; Zhou M; Zhao X; Liu F; Jiang S; Huang J; Meng L
Int J Clin Pharm; 2024 Apr; 46(2):480-487. PubMed ID: 38245663
[TBL] [Abstract][Full Text] [Related]
17. Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System.
Zhao D; Long X; Wang J
Expert Opin Drug Saf; 2024 May; 23(5):599-605. PubMed ID: 38553867
[TBL] [Abstract][Full Text] [Related]
18. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database.
Sun R; Ning Z; Qin H; Zhang W; Teng Y; Jin C; Liu J; Wang A
Sci Rep; 2024 Apr; 14(1):9552. PubMed ID: 38664423
[TBL] [Abstract][Full Text] [Related]
19. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Online Patient Reviews and National Pharmacovigilance Data for Tramadol-Related Adverse Events: Comparative Observational Study.
Park S; Choi SH; Song YK; Kwon JW
JMIR Public Health Surveill; 2022 Jan; 8(1):e33311. PubMed ID: 34982723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]